Kissei Pharmaceutical Co Ltd (JP:4547)
:4547
Want to see JP:4547 full AI Analyst Report?
Top Page
Kissei Pharmaceutical Co
(4547)
Select Model
Select Model
Rating:79Outperform
Price Target:
¥5,330.00
▲(15.62% Upside)
Action:UpgradedDate:11/28/25
Kissei Pharmaceutical's overall score of 79 reflects a strong financial profile with robust revenue growth and a stable balance sheet as the primary drivers. Positive technical momentum further supports the score, while a reasonable P/E ratio and solid dividend yield add to the favorable outlook. However, risks from inconsistent EBIT growth and cash flow volatility slightly limit the upside.
Positive Factors
Revenue Growth
Strong revenue growth indicates successful market penetration and demand for Kissei's products, supporting long-term business expansion.
Negative Factors
Cash Flow Generation
Low free cash flow generation relative to net income suggests potential challenges in converting earnings into cash, which may impact future investments.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Strong revenue growth indicates successful market penetration and demand for Kissei's products, supporting long-term business expansion.
Read all positive factors
Kissei Pharmaceutical Co (4547) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥194.02B
Dividend Yield2.48%
Average Volume (3M)67.88K
Price to Earnings (P/E)14.9
Beta (1Y)0.50
Revenue Growth13.11%
EPS Growth41.57%
CountryJP
Employees1,779
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)N/A
Shares Outstanding46,541,985
10 Day Avg. Volume76,260
30 Day Avg. Volume67,883
Financial Highlights & Ratios
PEG Ratio1.25
Price to Book (P/B)0.80
Price to Sales (P/S)1.90
P/FCF Ratio83.28
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥5,600.00Price Target Upside21.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Kissei Pharmaceutical Co Business Overview & Revenue Model
Company Description
Kissei Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products primarily in Japan. It offers Urief and Urief OD tablets for the treatment of dysuria; Glufast, Glubes, and Marizev tablets for ...
How the Company Makes Money
Kissei Pharmaceutical generates revenue primarily through the sale of its pharmaceutical products, which are distributed both domestically in Japan and internationally. The company’s revenue model is based on direct sales of prescription medicatio...
Kissei Pharmaceutical Co Financial Statement Overview
Summary
Income Statement
75
Positive
Balance Sheet
85
Very Positive
Cash Flow
65
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 89.36B | 88.33B | 75.58B | 67.49B | 65.38B | 69.04B |
| Gross Profit | 44.26B | 44.06B | 37.34B | 32.38B | 31.24B | 32.72B |
| EBITDA | 20.37B | 20.25B | 18.72B | 17.81B | 20.26B | 10.65B |
| Net Income | 12.37B | 11.96B | 11.16B | 10.53B | 12.92B | 5.29B |
Balance Sheet | ||||||
| Total Assets | 243.67B | 244.06B | 260.93B | 221.20B | 238.09B | 268.86B |
| Cash, Cash Equivalents and Short-Term Investments | 48.75B | 48.65B | 45.93B | 49.60B | 53.15B | 44.45B |
| Total Debt | 1.77B | 1.60B | 1.73B | 1.95B | 1.98B | 2.18B |
| Total Liabilities | 35.43B | 33.93B | 39.79B | 26.38B | 35.91B | 48.90B |
| Stockholders Equity | 207.09B | 209.00B | 220.03B | 193.90B | 201.39B | 219.31B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 2.01B | -2.88B | -8.78B | 44.00M | -3.47B |
| Operating Cash Flow | 0.00 | 6.52B | -1.68B | -6.68B | 1.53B | -2.54B |
| Investing Cash Flow | 0.00 | 4.95B | 8.69B | 6.00B | 10.78B | -9.33B |
| Financing Cash Flow | 0.00 | -9.32B | -10.01B | -3.42B | -2.76B | -4.00B |
Kissei Pharmaceutical Co Technical Analysis
Positive
4610.00
Price Trends
4619.88
Positive
4573.42
Positive
4344.19
Positive
Market Momentum
60.17
Negative
60.86
Neutral
58.10
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4547, the sentiment is Positive. The current price of 4610 is below the 20-day moving average (MA) of 4713.97, below the 50-day MA of 4619.88, and above the 200-day MA of 4344.19, indicating a bullish trend. The MACD of 60.17 indicates Negative momentum. The RSI at 60.86 is Neutral, neither overbought nor oversold. The STOCH value of 58.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4547.
Kissei Pharmaceutical Co Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | ¥149.12B | 93.62 | -2.58% | 4.16% | -5.99% | -96.04% | |
79 Outperform | ¥194.02B | 14.92 | 6.70% | 2.48% | 13.11% | 41.57% | |
73 Outperform | ¥121.48B | 12.60 | 4.81% | 2.34% | 4.35% | 48.30% | |
69 Neutral | ¥86.12B | 8.41 | ― | 3.36% | 11.65% | 93.46% | |
67 Neutral | ¥208.92B | 5.05 | 12.02% | 2.14% | 9.32% | 30.85% | |
59 Neutral | ¥217.79B | 13.89 | ― | 2.28% | 12.78% | -105.43% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
JP:4547
Kissei Pharmaceutical Co
4,650.00
946.16
25.55%
JP:4521
Kaken Pharmaceutical Co
4,085.00
137.05
3.47%
JP:4553
Towa Pharmaceutical Co
4,175.00
1,671.18
66.75%
JP:4534
Mochida Pharmaceutical Co., Ltd.
3,510.00
505.20
16.81%
JP:4569
KYORIN Pharmaceutical Co.,Ltd.
1,605.00
180.39
12.66%
JP:4887
SAWAI GROUP HOLDINGS Co., Ltd.
2,174.00
219.61
11.24%
Kissei Pharmaceutical Co Corporate Events
Kissei Wins Japan Approval for Oral GnRH Antagonist Yselty for Uterine Fibroids
Dec 22, 2025
Kissei Pharmaceutical has obtained Japanese manufacturing and marketing authorization for Yselty Tablets 100 mg (linzagolix choline), an oral GnRH antagonist indicated for the treatment of uterine fibroids, following successful domestic Phase III ...
Kissei Pharmaceutical Adjusts Dividend Payment Date
Dec 1, 2025
Kissei Pharmaceutical Co., Ltd. announced a change in the scheduled date for commencing dividend payments, moving it from December 3, 2025, to December 2, 2025. This adjustment is intended to readjust administrative procedures related to dividend ...
Kissei Pharmaceutical Co Reports Growth Amid Increased R&D Investment
Nov 5, 2025
Kissei Pharmaceutical Co reported a 7.9% year-over-year increase in net sales for the first half of fiscal 2025, driven by growth in both its pharmaceutical and other business segments. Despite a net operating loss, the company saw a significant r...
Kissei Pharmaceutical Revises Financial Forecast with Positive Outlook
Nov 4, 2025
Kissei Pharmaceutical Co., Ltd. has revised its financial forecast for the fiscal year ending March 31, 2026, reflecting an optimistic outlook with increased net sales and improved profit expectations. The company anticipates a rise in net sales b...
Kissei Pharmaceutical Reports Financial Results with Increased Net Sales
Nov 4, 2025
Kissei Pharmaceutical Co. reported its consolidated financial results for the six months ending September 30, 2025, showing a 7.9% increase in net sales compared to the previous year, despite operating and ordinary profits being negative. The comp...
Kissei’s Linzagolix Gains Marketing Approval in Taiwan
Oct 23, 2025
Kissei Pharmaceutical Co., Ltd. announced that its GnRH antagonist, Linzagolix, has been approved for marketing in Taiwan under the brand name Yselty, for the treatment of uterine fibroids. This approval, granted to Synmosa Biopharma Corporation, ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.